Quipt Announces Revocation of Management Cease Trade Order

3 years ago

CINCINNATI, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (“Quipt” or the “Company”) (NASDAQ:QIPT; TSXV:QIPT), a U.S. based…

Humacyte Announces Clinical Case Series Demonstrating Potential of Human Acellular Vessel™ (HAV™) to Expand Opportunities for Limb Salvage in Multiple Complex Vascular Reconstruction Scenarios

3 years ago

– Outcomes of first eight compassionate use cases presented at 46th Annual Winter Meeting of the Vascular and Endovascular Surgery Society…

Biogen Announces Nancy Leaming and Brian Posner to Retire from Board of Directors

3 years ago

CAMBRIDGE, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that Nancy Leaming and Brian Posner…

InteliSwab® COVID-19 Rapid Tests Receive U.S. FDA Authorization for Pediatric Use and Company Launches New InteliSwab® Connect Reporting App

3 years ago

InteliSwab test With less than one minute of “hands-on time,” the InteliSwab test is as simple as “Swab, Swirl, and…

Jushi Holdings Inc. Launches Investor Video Update Series

3 years ago

Innovative series to highlight Jushi’s leading operational footprint, national expansion plans, and M&A strategy BOCA RATON, Fla., Jan. 31, 2022…

Athira Pharma Announces Appointment of Grant Pickering to its Board of Directors

3 years ago

BOTHELL, Wash., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on…

Positive Topline Phase 3 MAESTRO-NAFLD-1 Data Demonstrate Resmetirom was Safe, Well-Tolerated and Provided Statistically Significant Improvements in Key Measures of Liver and Cardiovascular Health

3 years ago

Primary and key secondary endpoints from the double-blind placebo-controlled 969-patient MAESTRO-NAFLD-1 safety study were achieved and demonstrate that resmetirom: Was…

XORTX Provides Corporate Update

3 years ago

Synopsis of 2021 Achievements and Key Activities for 2022CALGARY, Alberta, Jan. 31, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX"…

Aravive Announces First Patient Dosed in Phase 2 Study of Batiraxcept in Clear Cell Renal Cell Carcinoma

3 years ago

Preliminary top line data anticipated throughout 2022HOUSTON, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage…

Passage Bio to Showcase GM1 Gangliosidosis and Krabbe Clinical Programs at 2022 WORLDSymposium, February 7 – 11

3 years ago

Late-breaker presentation to include new clinical data from Cohort 1 in the Imagine-1 clinical trial for GM1 gangliosidosis, Friday, February…